Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need.

Cognitive-behavioral therapy (CBT) is effective in the treatment of anxiety disorders when used in conjunction with benzodiazepine pharmacotherapy and when used as a monotherapy. Patients using CBT alone have dropout rates similar to or lower than those patients undergoing other forms of therapy, including benzodiazepines. CBT also works well with patients who do not respond adequately to pharmacotherapy. Combined CBT and benzodiazepine treatment has additive effects when compared with benzodiazepine monotherapy; however, patients receiving combined therapy who subsequently discontinue benzodiazepine treatment experience a loss of efficacy compared with CBT and placebo, perhaps due to fear extinction being context dependent. To avoid this loss of efficacy, CBT may be administered alone or as a bridge between benzodiazepine use and discontinuation during a medication taper. The case report upon which this supplement is based questions the value of CBT for patients experiencing cognitive impairment due to an anxiety disorder, benzodiazepine medication, substance abuse, or a combination of these factors. This article addresses this concern and asserts that CBT is a valuable treatment option in these cases.

[1]  M. Pollack,et al.  Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. , 1999, Behaviour research and therapy.

[2]  M. Otto,et al.  Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: a case series. , 2001, Behaviour research and therapy.

[3]  M. Pollack,et al.  Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment , 1996 .

[4]  Richard A. Brown,et al.  Anxiety sensitivity, self-reported motives for alcohol and nicotine use, and level of consumption. , 2003, Journal of anxiety disorders.

[5]  M K Shear,et al.  Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. , 2000, JAMA.

[6]  W. Rinn,et al.  Addiction denial and cognitive dysfunction: a preliminary investigation. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[7]  State-dependent fear extinction with two benzodiazepine tranquilizers. , 1990 .

[8]  C. Brewin,et al.  Alprazolam and Exposure for Panic Disorder with Agoraphobia , 1994, British Journal of Psychiatry.

[9]  M. Horner,et al.  Substance abuse treatment outcomes for cognitively impaired and intact outpatients , 2002 .

[10]  J. Rosenbaum,et al.  Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. , 1993, The American journal of psychiatry.

[11]  M. Pollack,et al.  A meta-analysis of treatment outcome for panic disorder , 1995 .

[12]  H. Curran.  Tranquillising memories: A review of the effects of benzodiazepines on human memory , 1986, Biological Psychology.

[13]  J. Rosenbaum,et al.  Cognitive behavior therapy for treatment-refractory panic disorder. , 1994, The Journal of clinical psychiatry.

[14]  H. Valerie Curran,et al.  Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil , 2005, Psychopharmacology.

[15]  A. Hiltunen,et al.  Neuropsychological changes during steady‐state drug use, withdrawal and abstinence in primary benzodiazepine‐dependent patients , 1995, Acta psychiatrica Scandinavica.

[16]  M. Posternak,et al.  Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. , 2001, The American journal on addictions.

[17]  M. Otto.  Learning and “unlearning” fears: preparedness, neural pathways, and patients , 2002, Biological Psychiatry.

[18]  L. Judd,et al.  A neuropsychological study of panic disorder: negative findings. , 1998, Journal of affective disorders.

[19]  M. Vasey,et al.  Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. , 2002, Behaviour research and therapy.

[20]  S. Lucente,et al.  Effect of neurocognitive status and personality functioning on length of stay in residential substance abuse treatment: An integrative study. , 1994 .

[21]  R. Block,et al.  Alprazolam and lorazepam effects on memory acquisition and retrieval processes , 1984, Pharmacology Biochemistry and Behavior.

[22]  S. Borg,et al.  Neuropsychological impairment and exclusive abuse of sedatives or hypnotics. , 1980, The American journal of psychiatry.

[23]  Samantha A. Stewart.  The effects of benzodiazepines on cognition. , 2005, The Journal of clinical psychiatry.

[24]  K. Kobak,et al.  Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis , 1998, Psychopharmacology.

[25]  A. Nuzzarello,et al.  Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? , 1994, The American journal of psychiatry.

[26]  M. Keller,et al.  Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? , 2003, The American journal of psychiatry.

[27]  J. Lucas,et al.  Memory functioning in panic disorder: A neuropsychological perspective , 1991 .

[28]  Marsha E. Bates,et al.  Neurocognitive impairment associated with alcohol use disorders: implications for treatment. , 2002, Experimental and clinical psychopharmacology.

[29]  M. Stein,et al.  Neurocognitive function in panic disorder and social phobia patients. , 1994, Anxiety.

[30]  S. File,et al.  Do lorazeam-induced deficits in learning result from impaired rehearsal, reduced motivation or increased sedation? , 1982, British journal of clinical pharmacology.

[31]  J. Davis,et al.  Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change. , 1999, Journal of psychoactive drugs.

[32]  M. Pollack,et al.  Cognitive-Behavioral and Pharmacological Treatment for Social Phobia: A Meta-Analysis , 1997 .

[33]  M. Hegel,et al.  Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder , 1994 .

[34]  D. Ciraulo,et al.  Critical review of liability for benzodiazepine abuse among alcoholics. , 1988, The American journal of psychiatry.

[35]  Edward Nunes,et al.  Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. , 2003, Drug and alcohol dependence.

[36]  P. Lelliott,et al.  Alprazolam and Exposure Alone and Combined in Panic Disorder with Agoraphobia , 1993, British Journal of Psychiatry.

[37]  M. Bouton.  Context, ambiguity, and unlearning: sources of relapse after behavioral extinction , 2002, Biological Psychiatry.

[38]  M. Pollack,et al.  Internal cue exposure and the treatment of substance use disorders: lessons from the treatment of panic disorder. , 2004, Journal of anxiety disorders.

[39]  Jasper A. J. Smits,et al.  Combined Psychotherapy and Pharmacotherapy for Mood and Anxiety Disorders in Adults: Review and Analysis , 2006 .

[40]  H. Westra,et al.  Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety? , 1998, Clinical psychology review.

[41]  M. Biondi,et al.  Attribution of Improvement to Medication and Increased Risk of Relapse of Panic Disorder with Agoraphobia , 2003, Psychotherapy and Psychosomatics.

[42]  Laura L. Vernon,et al.  Changes in caffeine states enhance return of fear in spider phobia. , 2003, Journal of consulting and clinical psychology.